Orally Active Fusion Inhibitor of Respiratory Syncytial Virus

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 413-422

  Cianci, Christopher ^a   Yu, Kuo Long ^a,b   Combrink, Keith ^a,c   Sin, Ny ^a   Pearce, Bradley ^a   Wang, Alan ^a   Civiello, Rita ^a   Voss, Stacey ^a   Luo, Guangxiang ^a   Kadow, Kathy ^a   Genovesi, Eugene V ^a   Venables, Brian ^a   Gulgeze, Hatice ^a   Trehan, Ashok ^a   James, Jennifer ^a   Lamb, Lucinda ^a   Medina, Ivette ^a   Roach, Julia ^a   Yang, Zheng ^a   Zadjura, Lisa ^a   Colonno, Richard ^a   Clark, Junius ^a   Meanwell, Nicholas ^a   Krystal, Mark ^a   more..

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Cumbre Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BIS(5 AMIDINO 2 BENZIMIDAZOLYL)METHANE; BMS 233675; BMS 2434588; BMS 433771; COMPLEMENTARY DNA; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; VIRUS FUSION PROTEIN; VIRUS FUSION PROTEIN F1 SUBUNIT; VIRUS PROTEIN;

ADOLESCENT; ANIMAL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; BIOSYNTHESIS; CHROMOSOME MAP; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; GENE MUTATION; GENETICS; GENOTYPE; GIANT CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID MEMBRANE; LUNG INFECTION; MEMBRANE FUSION; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SYNCYTIUM; TEMPERATURE; VIROLOGY; VIRUS CULTURE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHROMOSOME MAPPING; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DRUG RESISTANCE, VIRAL; GENOTYPE; GIANT CELLS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLAQUE ASSAY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; TEMPERATURE; VIRAL FUSION PROTEINS; VIRAL PROTEINS;

EID: 9144234679     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.413-422.2004     Document Type: Article

References (68)

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, and J. A. Smith. 1989. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y.
2. Byrd, L. G., and G. A. Prince. 1997. Animal models of respiratory syncytial virus infection. Clin. Infect. Dis. 25:1363-1368.
3. Calder, L. J., L. Gonzalez-Reyes, B. Garcia-Barreno, S. A. Wharton, J. J. Skehel, D. C. Wiley, and J. A. Melero. 2000. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:122-131.
4. Carr, C. M., and P. S. Kim. 1993. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 73:823-832.
5. Chambers, P., C. R. Pringle, and A. J. Easton. 1992. Sequence analysis of the gene encoding the fusion glycoprotein of pneumonia virus of mice suggests possible conserved secondary structure elements in paramyxovirus fusion glycoproteins. J. Gen. Virol. 73:1717-1724.
6. Chanock, R. M., and R. H. Parrott. 1965. Acute respiratory disease in infancy and childhood: present understanding and prospects for prevention. Pediatrics 36:21-39.
7. Cianci, C., K. L. Yu, D. D. Dischino, W. Harte, M. Deshpande, G. Luo, R. J. Colonno, N. A. Meanwell, and M. Krystal. 1999. pH-dependent changes in photoaffinity labeling patterns of the HI influenza virus hemagglutinin by using an inhibitor of viral fusion. J. Virol. 73:1785-1794.
8. Collins, P. L., M. G. Hill, E. Camargo, H. Grosfeld, R. M. Chanock, and B. R. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA 92:11563-11567.
9. Collins, P. L., K. McIntosh, and R. M. Chanock. 2001. Respiratory syncytial virus. p. 1443-1486. In D. M. Knipe and P. M. Howley (ed.), Virology. 3rd ed. Raven Press, New York, N.Y.
10. De Clercq, E. 2001. Antiviral drugs: current state of the art. J. Clin. Virol. 22:73-89.
11. Douglas, J. L., M. L. Panis, E. Ho, K. Y. Lin, S. H. Krawczyk, D. M. Grant, R. Cai, S. Swaminathan, and T. Cihlar. 2003. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Virol. 77:5054-5064.
12. Dowell, S. F., L. J. Anderson, H. E. J. Gary, D. D. Erdman, J. F. Plouffe, T. M. J. File, B. J. Marston, and R. F. Breiman. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174:456-462.
13. DuBovi, E. J., J. D. Geratz, S. R. Shaver, and R. R. Tidwell. 1981. Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines. Antimicrob. Agents Chemother. 19:649-656.
14. DuBovi, E. J., J. D. Geratz, and R. R. Tidwell. 1980. Inhibition of respiratory syncytial virus by bis(5-amidino-2-benzimidazolyl)methane. Virology 103:502-504.
15. Dutch, R. E., T. S. Jardetzky, and R. A. Lamb. 2000. Virus membrane fusion proteins: biological machines that undergo a metamorphosis. Biosci. Rep. 20:597-612.
16. Englund, J. A., C. J. Sullivan, M. C. Jordan, L. P. Dehner, G. M. Vercellotti, and H. H. Balfour. 1988. Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 109:203-208.
17. Falsey, A. R., C. K. Cunningham, W. H. Barker, R. W. Kouides, J. B. Yuen, M. Menegus, L. B. Weiner, C. A. Bonville, and R. F. Betts. 1995. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:389-394.
18. Falsey, A. R., J. J. Treanor, R. F. Betts, and E. E. Walsh. 1992. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40:115-119.
19. Falsey, A. R., and E. E. Walsh. 2000. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13:371-384.
20. Garcia, R., I. Raad, D. Ahi-Said, G. Bodey, R. Champlin, J. Tarrand, L. A. Hill, J. Umphrey, J. Neumann, J. Englund, and E. Whimhey. 1997. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect. Control Hosp. Epidemiol. 18:412-416.
21. Glezen, W. P., L. H. Taher, A. L. Frank, and J. A. Kasel. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:543-546.
22. Greenough, A. 2001. Recent advances in the management and prophylaxis of respiratory syncytial virus infection. Acta Paediatr. Suppl. 90:11-14.
23. Greenough, A., and M. Thomas. 2000. Respiratory syncytial virus prevention: past and present strategies. Expert Opin. Pharmacother. 1:1195-1201.
24. Hacking, D., and J. Hull. 2002. Respiratory syncytial virus-viral biology and the host response. J. Infect. 45:18-24.
25. Heikkinen, T., M. Thint, and T. Chonmaitree. 1999. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N. Engl. J. Med. 340:260-264.
26. Holherg, C. J., A. L. Wright, F. D. Martinez, C. G. Ray, L. M. Taussig, and M. D. Lehowitz. 1991. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 133:1135-1151.
27. Huntley, C. C., W. J. Weiss, A. Gazumyan, A. Buklan, B. Feld, W. Hu, T. R. Jones, T. Murphy, A. A. Nikitenko, B. O'Hara, G. Prince, S. Quartuccio, Y. E. Raifeld, P. Wyde, and J. F. O'Connell. 2002. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. 46:841-847.
28. Ikeda, S., J. Neyts, S. Verma, A. Wickramasinghe, P. Mohan, and E. De Clercq. 1994. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob. Agents Chemother. 38:256-259
29. Johnson, S., C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S.-C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, and J. F. Young. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
30. Kahn, J. S., M. J. Schnell, L. Buonocore, and J. K. Rose. 1999. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254:81-91.
31. Kilhy, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
32. Kilhy, J. M., J. P. Lalezari, J. J. Eron, M. Carlson, C. Cohen, R. C. Arduino, J. C. Goodgame, J. E. Gallant, P. Volherding, R. L. Murphy, F. Valentine, M. S. Saag, E. L. Nelson, P. R. Sista, and A. Dusek. 2003. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retrovir. 19:685-693.
33. Kimura, K., S. Mori, K. Tomita, K. Ohno, K. Takahashi, S. Shigeta, and M. Terada. 2000. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antivir. Res. 47:41-51.
34. Lalezari, J. P., K. Henry, M. O'Hearn, J. S. Montaner, P. J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, Jr., J. Chung, R. DeMasi, L. Donatacci, C. Drohnes, J. Delehanty, and M. Salgo. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
35. Lawless-Delmedico, M. K., P. Sista, R. Sen, N. C. Moore, J. B. Antczak, J. M. White, R. J. Greene, K. C. Leanza, T. J. Matthews, and D. M. Lambert. 2000. Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex. Biochemistry 39:11684-11695.
36. Luo, G., R. Colonno, and M. Krystal. 1996. Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Virology 226:66-76.
37. Luo, G. X., A. Torri, W. E. Harte, S. Danetz, C. Cianci, L. Tiley, S. Day, D. Mullaney, K. L. Yu, C. Ouellet, P. Dextraze, N. Meanwell, R. Colonno, and M. Krystal. 1997. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J. Virol. 71:4062-4070.
38. Martin, M. A., M. J. Bock, M. A. Pfaller, and R. P. Wenzel. 1988. Respiratory syncytial virus infections in adult bone marrow transplant recipients. Lancet i:1396-1397.
39. Mathur, U., D. W. Bentley, and C. B. Hall. 1980. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann. Intern. Med. 93:49-52.
40. Matthews, J. M., T. F. Young, S. P. Tucker, and J. P. Mackay. 2000. The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J. Virol. 74:5911-5920.
41. McKimm-Breschkin, J. 2000. VP-14637 ViroPharma. Curr. Opin. Investig. Drugs 1:425-427.
42. Mills, J. 1996. Management of respiratory syncytial virus infections. Plenum Press, New York, N.Y.
43. Moyse, E., M. Lyon, G. Cordier, J. F. Mornex, L. Collet, and P. Froehlich. 2000. Viral RNA in middle ear mucosa and exudates in patients with chronic otitis media with effusion. Arch. Otolaryngol. Head Neck Surg. 126:1105-1110.
44. Murry, A. R., and S. F. Dowell. 1997. Respiratory syncytial virus: not just for kids. Hosp. Pract. 15:87-88.
45. Osiowy, C., and R. Anderson. 1995. Neutralization of respiratory syncytial virus after cell attachment. J. Virol. 69:1271-1274.
46. Osterweil, D., and D. Norman. 1990. An outbreak of an influenza-like illness in a nursing home. J. Am. Geriatr. Soc. 38:659-662.
47. Pagani, F., and F. Sparatore. 1965. Benzotriazolyl-alkyl-benzimidazoles and their dialkyl-aminoalkyl derivatives. Boll. Chim. Farm. 104:427-431.
48. Paglietti, G., V. Boido, and F. Sparatore. 1975. Dialkylaminoalkylbenzimidazoles of pharmacological importance. IV. Il Farmaco 30:505-511.
49. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
50. Plotch, S. J., B. O'Hara, J. Morin, O. Palant, J. LaRocque, J. D. Bloom, S. A. Lang, Jr., M. J. DiGrandi, M. Bradley, R. Nilakantan, and Y. Gluzman. 1999. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J. Virol. 73:140-151.
51. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
52. Prince, G. A. 2001. An update on respiratory syncytial virus antiviral agents. Expert Opin. Investig. Drugs 10:297-308.
53. Schmidt, A. C., R. B. Couch, G. J. Galasso, F. G. Hayden, J. Mills, B. R. Murphy, and R. M. Chanock. 2001. Current research on respiratory viral infections: Third International Symposium. Antivir. Res. 50:157-196.
54. Sigurs, N. 2001. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med. 163: S2-S6.
55. Sigurs, N., R. Bjarnason, F. Sigurbergsson, B. Kjellman, and B. Bjorksten. 1995. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 95:500-505.
56. Simoes, E. A. 2001. Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes. Am. J. Respir. Crit. Care Med. 163:S14-S17.
57. Smith, B. J., M. C. Lawrence, and P. M. Colman. 2002. Modeling the structure of the fusion protein from human respiratory syncytial virus. Protein Eng. 15:365-371.
58. Sorvillo, F. J., S. F. Huie, M. A. Strassburg, A. Butsumyo, W. X. Shandera, and S. L. Fannin. 1984. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J. Infect. 9:252-256.
59. Staschke, K. A., S. D. Hatch, J. C. Tang, W. J. Hornback, J. E. Munroe, J. M. Colacino, and M. A. Muesing. 1998. Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. Virology 248:264-274.
60. Sudo, K., K. Konno, W. Watanabe, S. Shigeta, and T. Yokota. 2001. Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbiol. Immunol. 45:531-537.
61. Taylor, G., E. J. Stott, M. Hughes, and A. P. Collins. 1984. Respiratory syncytial virus infection in mice. Infect. Immun. 43:649-655.
62. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186.
63. Tidwell, R. R., J. D. Geratz, W. A. Clyde, K. U. Rosenthal, and E. J. Dubovi. 1984. Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane. Antimicrob. Agents Chemother. 26:591-593.
64. Tidwell, R. R., J. D. Geratz, and E. J. Dubovi. 1983. Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin. J. Med. Chem. 26:294-298.
65. Treanor, J., and A. Falsey. 1999. Respiratory viral infections in the elderly. Antivir. Res. 44:79-102.
66. Weiss, W. J., T. Murphy, M. E. Lynch, J. Frye, A. Buklan, B. Gray, E. Lenoy, S. Mitelman, J. O'Connell, S. Quartuccio, and C. Huntley. 2003. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J. Med. Primatol. 32:82-88.
67. Yu, K. L., Y. Zhang, R. L. Civiello, K. Kadow, C. Cianci, M. Krystal, and N. A. Meanwell. 2003. Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorg. Med. Chem. Lett. 13:2141-2144.
68. Zhao, X., M. Singh, V. N. Malashkevich, and P. S. Kim. 2000. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. USA 97:14172-14177.